Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer

Experimental and Molecular Pathology

Volumn 87, Issue 3, 2009, Pages 226-233

  de Castro, Javier ^a   Rodríguez, Marina C ^a   Martínez Zorzano, Vicenta S ^b   Llanillo, Marcial ^c   Sánchez Yagüe, Jesús ^c  

^a Unidad de Mama Hospital de la Santísima Trinidad   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cytokeratins; Erythrocyte; Fatty acids; Non small cell lung cancer; Platelet; Sialic acid; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; FATTY ACID; LINOLEIC ACID; SIALIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHMA; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ERYTHROCYTE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE;

AGED; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; ERYTHROCYTES; FEMALE; HUMANS; LINOLEIC ACID; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 70350565464     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.08.002     Document Type: Article

References (49)

1. Alatas F., Alatas Ö., Metintas M., Colak Ö., Harmanci E., and Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, Cygra 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31 (2001) 9-16
2. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 81 (1961) 384-392
3. Brittain J.E., Mlinar K.J., Anderson C.S., Orringer E.P., and Parise L.V. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J. Clin. Invest. 107 (2001) 1555-1562
4. Buccheri G., and Ferrigno D. Cytokeratin-derived markers of lung cancer. Expert Rev. Mol. Diagn. 1 (2001) 315-322
5. Buccheri G., and Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 34 (2001) S65-S69
6. Burgueño M.J., García-Bastos J.L., and González-Biutrago J.L. Las curvas ROC en la evaluación de las pruebas diagnósticas. Med. Clin. (Barc.) 104 (1995) 661-670
7. Calikoglu M., Unlu A., Tamer L., Ercan B., Bugdayci R., and Atik U. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin. Chem. Lab. Med. 40 (2002) 1028-1031
8. Chen M., and Hofestadt R. A medical bioinformatics approach for metabolics disorders. Biomedical data prediction, modelling, and systematic analysis. J. Biomed. Inform. 39 (2006) 147-159
9. Crawford J.H., Chacko B.K., Kevil C.G., and Patel R.P. The red blood cell and vascular function in health and disease. Antioxid. Redox Signal. 6 (2004) 992-999
10. Das U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J. 1 (2006) 420-439
11. de Castro J., Hernández-Hernández A., Rodríguez M.C., Llanillo M., and Sánchez-Yagüe J. Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest. 24 (2006) 339-345
12. de Castro J., Hernández-Hernández A., Rodríguez M.C., Sardina J.L., Llanillo M., and Sánchez-Yagüe J. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 18 (2007) 43-51
13. de Castro J., Rodríguez M.C., Martínez-Zorzano V.S., Hernández-Hernández A., Llanillo M., and Sánchez-Yagüe J. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer. Comparison with serum levels of sialic acid, TPS and Cyfra 21-1. Cancer Invest. 26 (2008) 407-418
14. Erceq-Hurn D.M., and Mirosevich V.M. Modern robust statistical methods: an easy way to maximize the accuracy and power of your research. Am. Phychol. 63 (2008) 591-601
15. Feijoo-Carnero C., Rodríguez-Berrocal F.J., Páez de la Cadena M., Ayude D., de Carlos A., and Martínez-Zorzano V.S. Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence. Int. J. Biological Markers 19 (2004) 38-45
16. Fischer J.R., and Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 45 (2004) S151-S161
17. Gornall A.G., Bardawill C.J., and David M.M. Determination of serum proteins by means of Biuret reaction. J. Biol. Chem. 177 (1949) 751-766
18. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91 (1999) 1616-1634
19. Hernandez-Hernandez A., Llanillo M., Rodriguez M.C., Gomez F., and Sanchez-Yague J. Amphiphilic and hydrophilic nature of sheep and human platelet phosphotyrosine phosphatase forms. Biochim. Biophys. Acta 1419 (1999) 195-206
20. Hernandez-Hernandez A., Garabatos M.N., Rodríguez M.C., Vidal M.L., López-Revuelta A., Sánchez-Gallego J.I., Llanillo M., and Sanchez-Yagüe J. Structural characteristics of a lipid peroxidation product, trans-2-nonenal, that favour inhibition of membrane-associated phosphotyrosine phosphatase activity. Biochim. Biophys. Acta 1726 (2005) 317-325
21. Hernández-Hernández A., Rodríguez M.C., López-Revuelta A., Sánchez-Gallego J.I., Shnyrov V., Llanillo M., and Sánchez-Yagüe J. Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cell Mol. Dis. 36 (2006) 355-363
22. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
23. Kaplan K.L., and Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57 (1981) 199-202
24. Khyshiktuev B.S., Khyshiktueva N.A., Ivanov V.N., Darenskaia S.D., and Novikov S.V. Fatty acid composition of blood plasma lipids and erythrocytes in lung cancer patients. Vopr. Med. Khim. 40 (1994) 48-50
25. López-Revuelta A., Sánchez-Gallego J.I., Hernández-Hernández A., Sánchez-Yagüe J., and Llanillo M. Increase in vulnerability to oxidative damage in cholesterol-modified erythrocytes exposed to t-BuOOH. Biochim. Biophys. Acta 1734 (2005) 74-85
26. López-Revuelta A., Sánchez-Gallego J.I., García-Montero A.C., Hernández-Hernández A., Sánchez-Yagüe J., and Llanillo M. Membrane cholesterol in the regulation of aminophospholipid asymmetry and phagocytosis in oxidized erythrocytes. Free Radic. Biol. Med. 42 (2007) 1106-1118
27. Minetti M., Leto T.L., and malorni W. Radical generation and alterations of erythrocyte integrity as bioindicators of diagnostic or prognostic value in COPD?. Antioxid. Redox Signal. 10 (2008) 829-836
28. Mikirova N., Riordan H.D., Jackson J.A., Wong K., Miranda-Massari J.R., and Gonzalez M.J. Erythrocyte membrane fatty acid composition in cancer patients. P. R. Health Sci. J. 23 (2004) 107-113
29. Monge-Corella M., García-Pérez J., Aragonés N., Marina Pollán M., Beatriz Pérez-Gómez B., and López-Abente G. Lung cancer mortality in towns near paper, pulp and boardindustries in Spain: a point source pollution study. BMC Public Health 8 (2008) 288-298
30. Mosconi C., Agradi E., Gambetta A., Bozzetti F., and Galli C. Decrease of polyunsaturated fatty acids and elevation of the oleic/stearic acid ratio in plasma and red blood cell lipids of malnourished cancer patients. JPEN J. Parenter. Enteral. Nutr. 13 (1989) 501-504
31. Narayanan S. Sialic acid as a tumor marker. An. Cli. La. Sci. 24 (1994) 376-384
32. Newcomer L.M., King I.B., Wicklund K.G., and Stanford J.L. The association of fatty acids with prostate cancer risk. Prostate 47 (2001) 262-268
33. Pala V., Krogh V., Muti P., Chajes V., Riboli E., Micheli A., Saadatian M., Sieri S., and Berrino F. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J. Natl. Cancer Inst. 93 (2001) 1088-1095
34. Park S.H., God J.M., and Jo C.H. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J. Radiol. 5 (2004) 11-18
35. Patel P.S., Baxi B.R., and Balar D.B. Significance of serum sialoglycoproteins in patients with lung cancer. Neoplasma 36 (1989) 53-59
36. Patel P.S., Raval G.N., Rawal R.M., Patel G.H., Balar D.B., Shah P.M., and Patel D.D. Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer. Neoplasma 42 (1995) 271-274
37. Pidgeon G.P., Lysaght J., Krishnamoorthy S., Reynolds J.V., O ' Byrne K., Nie D., and Hoon K.V. Lipoxigenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26 (2007) 503-524
38. Plabani M., Basso D., Navaglia F., De Paoli M., Tommasini A., and Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improve the results?. Br. J. Cancer 72 (1995) 170-173
39. Prisco D., Rogasi P.G., Matucci M., Abbate R., Gensini G.F., and Serneri G.G. Increased thromboxane A2 generation and altered membrane fatty acid composition in platelets from patients with active angina pectoris. Throm. Res. 44 (1986) 101-112
40. Prisco D., Rogasi P.G., Paniccia R., Abbate R., Gensini G.F., Pinto S., Vanni D., and Neri-Serneri G.G. Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. Prostaglandins Leukot. Essent. Fatty Acids 35 (1989) 15-23
41. Prisco D., Paniccia R., Coppo M., Filippini M., Francalanci I., Brunelli T., Comeglio P., and Abbate R. Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukot. Essent. Fatty Acids 53 (1995) 65-68
42. Pujol J.L., Grenier J., Parrat E., Lehmann M., Lafontaine T., Quantin X., and Michel F.B. Cytoqueratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am. J. Respir. Crit. Care Med. 154 (1996) 725-733
43. Santos M.T., Valles J., Marcus A.J., Safier L.B., Broekman M.J., Islam N., Ullman H.L., Eiroa A.M., and Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J. Clin. Invest. 87 (1991) 571-580
44. Straface E., Masella R., Del Principe D., Franceschi C., Korkina L.G., Zatterale A., Pagano G., and Malorni W. Spectrin changes occur in erythrocytes from patients with Fanconi's anemia and their parents. Biochem. Biophys. Res. Commun. 273 (2000) 899-901
45. Straface E., Matarrese P., Gambardella L., Forte S., Carlone S., Libianchi E., Schmid G., and Malorni W. N-acetylcisteine counteracts erythrocyte alterations occurring in chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. 279 (2000) 552-556
46. Straface E., Rivabene R., Masella R., Santulli M., Paganelli R., and Malorni W. Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes. Protective effects of N-acetylcysteine. Biochem. Biophys. Res. Commun. 290 (2002) 1393-1398
47. Stringou E., Chondros K., Kouvaris J., Kakari S., and Papavassiliou K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. Anticancer Res. 12 (1992) 251-256
48. Warren L. The thiobarbituric acid assay of sialic acids. J. Biol. Chem. 234 (1959) 1971-1975
49. Yi L.Z., He J., Liang Y.Z., Yuan D.L., and Chau F.T. Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett. 580 (2006) 6837-6845